-
New Chimeric Phase 1B clinical trial of CHM 1101 receives approval from ethics review board
-
The Phase 1B trial will involve participation of multiple clinical sites
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only ASX-listed clinical stage cell therapy company, is pleased to announce that it has received ethics approval for the initiation of a multi-site Phase 1B clinical trial of CHM 1101 in patients with recurrent and/ or progressive glioblastoma multiforme (GBM).
This new chapter in the development of CHM 1101 will see Chimeric leading a two-part Phase 1B clinical study enrolling patients with recurrent and/ or progressive GBM at multiple clinical trial sites
For more information, download the attached PDF.
Download this document
